Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (65)

1

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

enthalten in: Cancer | 2024

von Nooka, A. | Rodriguez, C. | Mateos, M. | +9

2

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

3

GPRC5D as a novel target for the treatment of multiple myeloma : a narrative review

enthalten in: Blood cancer journal | 2024

von Rodriguez-Otero, P. | van de Donk, N. | Pillarisetti, K. | +13

ErratumIn: Blood Cancer J. 2024 Mar 6;14(1):40. - PMID 38448422

4

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation

enthalten in: Blood advances | 2024

von Frerichs, K. | Verkleij, C. | Mateos, M. | +21

5

T-cell-engaging bispecific antibodies in cancer

enthalten in: Lancet (London, England) | 2023

von van de Donk, N. | Zweegman, S.

6

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

enthalten in: Cancer | 2023

von Martin, T. | Mateos, M. | Nooka, A. | +12

7

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

8

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

9

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

enthalten in: Blood | 2023

von Cohen, A. | Mateos, M. | Cohen, Y. | +21

CommentIn: Blood. 2023 Jan 19;141(3):211-212. - PMID 36656612

10

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

enthalten in: The New England journal of medicine | 2022

von Chari, A. | Minnema, M. | Berdeja, J. | +17

CommentIn: N Engl J Med. 2022 Dec 15;387(24):2287-2290. - PMID 36507665

1
2
3
4
5
6
7
Nächster »
[7]